Sotera Health Posts Solid Q1, Reaffirms 2026 Outlook

Overview

• Sotera Health reported first-quarter results Tuesday with 6.5% constant-currency revenue growth, 6.9% adjusted EBITDA growth, and more than 20 basis points of margin expansion.
• Management kept its 2026 outlook for 5% to 6.5% revenue growth and 5.5% to 7% adjusted EBITDA growth.
• Sterigenics, the company’s sterilization arm, grew 6.1% with a 4.5% lift from pricing, while Nordion rose 25.8% on Cobalt-60 shipment timing rather than a structural surge.
• The company noted all eight Georgia bellwether injury cases tied to Sterigenics were dismissed, and it reported more than $900 million in available liquidity with net leverage at about 3.2 times.
• A CEO change to Alton Shader takes effect May 26 as the team advances capacity additions, a planned X-ray site, and onboarding of a large customer later this year.